Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while iShares 7-10 Year Treasury Bond ETF trades at $93.57. Which is the better fit depends on your goals.
| ALNY | IEF | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $97.99 |
52-Week Low | $278.09 | $93.11 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IEF trades at $93.63, down 0.09% on the day, with a bearish technical signal driven by moving averages. Recent news highlights bond market volatility amid shifting Fed rate expectations, with inflows into bond ETFs surging 60% year-over-year as of June 25, 2026 (CNBC). Dividend payments remain consistent, with the latest H1-26 payout at $0.32.
Outlook is cautious due to interest rate uncertainty; the Fed's potential hikes pose a headwind, but elevated demand for Treasury ETFs may provide support. Key risks include inflation persistence and geopolitical tensions impacting oil prices, as noted in Reuters and New York Post coverage on July 8, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
